AlphAIAlphAI — Financial news for AI agents
thepharmaletter.comSEP 282 min read$MRK

Merck & Co and SciBrunch sign deal worth up to $2.13 billion

Merck & Co (MRK) has signed a global license agreement with SciBrunch Therapeutics for the preclinical oral KRAS G12D (ON) inhibitor SPR2015. Merck will pay $400 million upfront and up to $2.13 billion in total, including milestone payments, for exclusive worldwide rights to develop, manufacture, and commercialize the drug.

Original reporting
thepharmaletter.com
Published Sep 28, 2026, 2:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 3:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Merck & Co and SciBrunch sign deal worth up to $2.13 billion — source image
Source · thepharmaletter.com
Decision brief

The 30-second read

$MRKBullishHigh
01

Why it matters

The transaction provides Merck immediate cash and future milestone upside, likely prompting a short‑term price rally.

02

Market read

A major licensing deal for a high‑value oncology asset, relevant for pharma investors and biotech sector sentiment.

03

What to watch

Regulatory timelines and potential competition from other KRAS inhibitors could moderate the impact.

Relevance 9/10Novelty 9/10Timing: pre‑market today

Background

Merck (MRK) expands its oncology pipeline through a $2.13B licensing deal with Chinese biotech SciBrunch.

Company-level read

Ticker impact

$MRKBullishHigh confidence
Context

Merck signed an exclusive global license with SciBrunch for SPR2015, paying $400M upfront and a total potential $2.13B.

Expected impact

upward pressure as investors price in the $400M upfront and future milestones.

Evidence & confidence

Large upfront cash and high total deal value for a preclinical asset represent material upside for Merck.

Market effects

Sector

Strengthens the oncology/precision‑medicine sector as big pharma backs KRAS programs.

Regional

May lift US pharma stocks and related biotech peers in Asia.

Global

Highlights continued US‑China biotech collaborations despite geopolitical tensions.

Counterpoint

What could challenge this read

If SPR2015 fails in later trials, the upfront payment could be seen as a sunk cost, limiting upside.

Key entities

  • Company
    Merck & Co

    US‑listed pharmaceutical giant (ticker MRK).

  • Company
    SciBrunch Therapeutics

    Chinese clinical‑stage biotech developing KRAS inhibitor SPR2015.

Read at source← All news

Also covered by

1 outlet

Related articles

SEP 28
$MRKMed

Merck’s Forward P/E Nearly Doubled to 17x in a Year. Here’s What Its Pipeline Must Deliver by 2030

Merck (MRK) and Daiichi Sankyo withdrew a U.S. approval application for their investigational cancer drug, citing insufficient data. Merck's stock is at $148.74, with a mid-target of $166 and a potential 12% total return. The company's pipeline is estimated to deliver $70B+ by the mid-2030s, but recent setbacks highlight risks. Analysts' FY2030 revenue estimates have risen to around $76B.

tikr.com3 min
SEP 28
$MRKMedAI 9/10

Merck closes SciBrunch KRAS licence for up to US$2.13B

Merck & Co. has closed a licence agreement with SciBrunch Therapeutics for worldwide rights to a preclinical KRAS G12D cancer drug, SPR2015, for up to $2.13B, including a $400M upfront payment. The deal includes potential milestone payments tied to development and commercialization. Merck shares traded at $147.79 on Sept. 28, with a $400M pre-tax charge expected in Q3 2026 results.

mugglehead.com2 min
SEP 28
$ABBVHighAI 8/10

AbbVie wins FDA nod for Parkinson’s pill

The FDA approved AbbVie's Parkinson's pill, tavapadon, to be sold as Juvmo. The drug is part of its $8.7 billion acquisition of Cerevel Therapeutics. AbbVie expects over $5 billion in combined sales from its Parkinson's portfolio, though analysts caution uptake may be gradual due to Medicare coverage negotiations.

statnews.com2 min
SEP 28
$MRKHighAI 9/10

Merck signs $2.13 billion KRAS cancer drug deal

Merck (MRK) signed a $2.13B deal with SciBrunch for exclusive global rights to SPR2015, a preclinical KRAS G12D inhibitor. The agreement includes a $400M upfront payment and potential milestone payments. Merck aims to expand its precision oncology pipeline with this targeted cancer therapy.

grafa.com2 min
SEP 28
$MRKMedAI 9/10

Merck (MRK) Secures Exclusive Global License for SPR2015, an Ora

Merck (MRK) secured a global license for SPR2015, an oral KRAS G12D inhibitor, from SciBrunch Therapeutics. The deal includes a $400M upfront payment and potential milestone payments totaling $2.13B. Merck's dividend yield is 2.31%, with a high payout ratio of 1.11, raising sustainability concerns. The stock is modestly overvalued by 23.1% according to GF Value™. Merck's GF Score™ is 81/100, reflecting strong profitability and growth.

gurufocus.com3 min